We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.31 | 1.34% | 99.04 | 99.075 | 98.54 | 98.60 | 671,495 | 18:09:35 |
From May 2019 to May 2024
By Jessica Sier
Novartis AG said Monday that it has acquired U.S.-based startup Amblyotech for an undisclosed sum.
The Swiss biotech company will partner with Ubisoft and McGill University to further develop a treatment of amblyopia, a lazy-eye disorder.
Amblyotech offers active-gaming and passive-video technology to train the eyes to view an image in full, said Novartis.
The Swiss company aims to develop Amblyotech's software into a medical device and conduct a proof of concept study.
Write to Jessica Sier at jessica.sier@wsj.com
(END) Dow Jones Newswires
April 20, 2020 01:50 ET (05:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
